applied molecular transport is developing a pipeline of transformative, targeted oral biological therapeutics that promise to redefine the future of biopharmaceuticals. our deep scientific foundations in mucosal immunology and microbiome-epithelial interfaces have led to the development of powerful technology platforms that are fueling a unique pipeline of first-in-class molecules to treat a wide range of grievous diseases. our oral biopharmaceutical products mimic the biology of microbial and other natural processes that modulate health and disease via mucosal immunology pathways. our targeted therapeutics are directed to the right location to intercept disease at the point of origin of dysregulation. we are advancing a pipeline of targeted oral biological therapeutics to treat autoimmune, inflammation and other diseases, including those associated with cancer, metabolic and hepatologic disorders. our overriding patient-centric goal is to open new biological possibilities based on nov
Company profile
Ticker
AMTI
Exchange
Website
CEO
Tahir Mahmood
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Applied Molecular Transport LLC
SEC CIK
Corporate docs
IRS number
814481426
AMTI stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
9 Jan 24
EFFECT
Notice of effectiveness
3 Jan 24
POSASR
Automatic shelf registration (post-effective amendment)
2 Jan 24
POS AM
Prospectus update (post-effective amendment)
2 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jan 24
25-NSE
Exchange delisting
28 Dec 23
8-K
Completion of Acquisition or Disposition of Assets
27 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
26 Dec 23
Latest ownership filings
SC 13G/A
Founders Fund V Management, LLC
14 Feb 24
SC 13D/A
EPIQ Capital Group, LLC
5 Jan 24
4
Chad Boeding
29 Dec 23
4
Aaron VanDevender
28 Dec 23
4
John W Smither
28 Dec 23
4
Holly Caren Schachner
28 Dec 23
4
Tahir Ph.D. Mahmood
28 Dec 23
4
Brandon Hants
28 Dec 23
4
Shawn Cross
28 Dec 23
4
Charlene A. Banard
28 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.10 mm | 18.10 mm | 18.10 mm | 18.10 mm | 18.10 mm | 18.10 mm |
Cash burn (monthly) | 1.45 mm | 4.90 mm | 2.41 mm | 6.38 mm | 1.47 mm | 5.00 mm |
Cash used (since last report) | 9.71 mm | 32.80 mm | 16.09 mm | 42.66 mm | 9.81 mm | 33.47 mm |
Cash remaining | 8.39 mm | -14.69 mm | 2.01 mm | -24.56 mm | 8.29 mm | -15.36 mm |
Runway (months of cash) | 5.8 | -3.0 | 0.8 | -3.9 | 5.7 | -3.1 |
Institutional ownership, Q3 2023
37.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 5 |
Closed positions | 7 |
Increased positions | 1 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 2.38 bn |
Total shares | 15.56 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
EPIQ Capital | 8.69 mm | $1.36 bn |
Founders Fund V Management | 3.61 mm | $567.02 mm |
Vanguard | 866.39 k | $136.02 mm |
Founders Fund VI Management | 826.61 k | $129.78 mm |
BLK Blackrock | 456.41 k | $71.66 mm |
Renaissance Technologies | 282.19 k | $44.00 k |
Laurion Capital Management | 217.83 k | $34.20 mm |
Geode Capital Management | 139.81 k | $21.95 mm |
HRT Financial | 113.31 k | $17.00 k |
Wealth Enhancement Advisory Services | 66.21 k | $10.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Dec 23 | Charlene A. Banard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.34 | 20,000 | 6.80 k | 0 |
27 Dec 23 | Charlene A. Banard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.13 | 20,000 | 62.60 k | 0 |
27 Dec 23 | Charlene A. Banard | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.52 | 60,000 | 451.20 k | 0 |
27 Dec 23 | Cross Shawn | Common Stock | Sale back to company | Dispose D | No | No | 0 | 545,499 | 0.00 | 0 |
27 Dec 23 | Cross Shawn | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.3936 | 668,000 | 262.92 k | 0 |
27 Dec 23 | Cross Shawn | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.99 | 84,000 | 335.16 k | 0 |
27 Dec 23 | Cross Shawn | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.29 | 94,500 | 783.40 k | 0 |
27 Dec 23 | Cross Shawn | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 56.61 | 63,000 | 3.57 mm | 0 |
27 Dec 23 | Cross Shawn | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.61 | 300,000 | 1.38 mm | 0 |
27 Dec 23 | Brandon Hants | Common Stock | Sale back to company | Dispose D | No | No | 0 | 301,225 | 0.00 | 0 |